Glycoligands for Unlocking the Next Generation of Targeted Therapeutics
NanoMedSyn develops AMFA glycoligands that specifically target the mannose 6-phosphate receptor (M6PR), opening the way for the creation of innovative therapeutic conjugates to address challenging undruggable targets and rare diseases
Engineering the Future of Precision Delivery and Targeted Protein Degradation
Our AMFA technology enables new mechanisms of action across major therapeutic classes by leveraging endogenous M6PR mediated trafficking:
- Therapeutic antibodies engineered with AMFA become first in class degraders capable of directing soluble or membrane pathogenic antigens to lysosomes for degradation
- Therapeutic nanoparticles modified with AMFA bind to the M6PR and are internalized into extra hepatic tissues, expanding the reach of RNA, enzymes, and other biologics
- Enzyme conjugated with AMFA mproves the lysosomal delivery of enzyme replacement therapy for rare metabolic diseases
By unlocking controlled intracellular routing, we open new frontiers in drug discovery to reach targets that were previously out of scope
Learn more about our advanced AMFA technology targeting M6PR to treat a wide range of pathologies